Advances in androgen receptor in treatment and prognosis of triple negative breast cancer
10.3781/j.issn.1000-7431.2018.55.285
- Author:
Yang LU
1
Author Information
1. Medical School of Ningbo University
- Publication Type:Journal Article
- Keywords:
Androgen;
Androgen receptor antagonists;
Breast neoplasms;
Prognosis;
Receptor
- From:
Tumor
2018;38(12):1155-1159
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) has a high degree of malignacy, and a higher incidence among young women. It is prone to early metastasis and chemotherapy tolerance, lacks effective clinical treatment targets, and has a poor prognosis. Many studies have found that androgen receptor (AR) can be highly expressed in TNBC tissues, which is closely related to the prognosis of TNBC. AR has been proved to promote the growth and metastasis of TNBC cells. The clinical data show that the single anti-androgen drug therapy shows the sensitivity to TNBC, and the combination of AR inhibitor and other classic targeted therapy drugs has potential value for the treatment of TNBC. Because AR is a reference indicator for the prognosis of TNBC, the studies on anti-AR therapy in TNBC have attracted considerable attention. This review discusses the therapeutic mechanism and clinical research of anti-AR therapy in TNBC.
